10373 studies found for:    NCI
Show Display Options
Rank Status Study
1 Completed
Has Results
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Condition: Untreated Childhood Brain Stem Glioma
Interventions: Radiation: radiation therapy;   Drug: tipifarnib
2 Recruiting Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Biological: ipilimumab;   Other: laboratory biomarker analysis
3 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Conditions: Stage IV Renal Cell Cancer;   Recurrent Renal Cell Cancer
Interventions: Drug: bevacizumab;   Drug: thalidomide
4 Completed Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Condition: Cancer
Intervention: Biological: recombinant interleukin-12
5 Terminated MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Terminated Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Other: laboratory biomarker analysis
7 Completed Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: alvocidib
8 Active, not recruiting Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Biological: ziv-aflibercept;   Drug: topotecan hydrochloride
9 Completed Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
10 Completed Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery
Condition: Lung Cancer
Interventions: Biological: recombinant fowlpox GM-CSF vaccine adjuvant;   Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;   Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: radiation therapy
11 Terminated Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
Conditions: Hematopoietic/Lymphoid Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alvocidib;   Other: pharmacological study;   Radiation: fludeoxyglucose F 18;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography
12 Completed
Has Results
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Other: laboratory biomarker analysis
13 Completed
Has Results
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Drug: ixabepilone
14 Completed Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;   Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Radiation: radiation therapy
15 Completed Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
16 Active, not recruiting Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
Conditions: Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate;   Drug: selumetinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Withdrawn Celecoxib in Preventing Skin Cancer
Condition: Non-melanomatous Skin Cancer
Interventions: Drug: celecoxib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological  therapy;   Procedure: cancer prevention intervention;   Procedure: chemoprevention of cancer;   Procedure: growth factor antagonist therapy
18 Active, not recruiting
Has Results
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
20 Active, not recruiting Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years